A novel perioperative comprehensive care model for elderly patients with lung cancer_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

LI Daiping ¹ , LIANG Rui ¹ , CHEN Nan ² , JIAO Peng ³ , TIAN Wenxin ³ , CHEN Yixiao ¹ , YUE Jirong ¹ , DONG Birong ¹ ,  LIU Lunxu ² ,  GE Ning ¹

1. Department of Geriatrics and National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, 610041, P. R. China;
2. Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China;
3. Department of Thoracic Surgery, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100005, P. R. China;

Corresponding?author：

LIU Lunxu, Email: lunxu_liu@aliyun.com; GE Ning, Email: grace7733@163.com

Keywords：

Elderly lung cancer; comprehensive geriatric assessment; perioperative period; treatment modality; frailty; delirium; sarcopenia; cognitive impairment; malnutrition

DOI：

10.7507/1007-4848.202605025

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

With the accelerating aging of the population, the proportion of elderly patients with lung cancer continues to rise, presenting multiple challenges to perioperative management. This paper systematically reviews the clinical characteristics of elderly lung cancer patients. Based on the comprehensive geriatric assessment, it proposes incorporating seven major geriatric syndromes—frailty, delirium, sarcopenia, cognitive impairment, malnutrition, dysphagia, and mood disorders—into the core evaluation system. By integrating multimorbidity management with complication prevention and control, an integrated "geriatric syndrome-multimorbidity-complication" perioperative management model is constructed. Furthermore, this paper outlines stratified intervention strategies for geriatric syndromes, a "five-step" workflow for comorbidity management, and a comprehensive intervention pathway for complications across the preoperative, intraoperative, and postoperative phases. Multidisciplinary team (MDT) collaboration serves as the core mechanism to achieve individualized comprehensive treatment. This paper aims to provide a novel perioperative comprehensive treatment model for elderly lung cancer patients, which is centered on geriatrics, supported by multidisciplinary collaboration, and guided by precision medicine.

1.	Cao Y, Tian Y, Li L. Perioperative immune checkpoint inhibitors in elderly patients with resectable NSCLC: a systematic review and meta-analysis. Front Oncol, 2025, 15: 1589846.
2.	Qi J, Li M, Wang L, et al. National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data. Lancet Public Health, 2023, 8(12): e943-e955.
3.	Gros L, Yip R, Ma W, et al. Surgical outcomes and quality of life in octogenarians with early-stage non-small cell lung cancer: a prospective cohort study. Lancet Reg Health Am, 2026, 56: 101428.
4.	Shi S, Yao J, Fu C, et al. The heterogeneous nutritional status trajectory and its predictors in elderly patients undergoing lung cancer surgery: a prospective cohort study. Front Nutr, 2026, 13: 1747612.
5.	Azem K, Fein S, Zribi B, et al. Additive value of superficial parasternal intercostal plane block and serratus anterior plane block in lung transplantation surgery: a retrospective exploratory study. Reg Anesth Pain Med, 2024: 105137.
6.	Li D, Sun CL, Kim H, et al. Geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults with cancer: a randomized controlled trial. J Clin Oncol, 2021, 7(11): e214158.
7.	Mohile SG, Mohamed MR, Xu H, et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet, 2021, 398(10314): 1894-1904.
8.	Bostock IC, Fox AH, Ward RC, et al. Outcomes after surgical management of early-stage lung cancer in octogenarians: an in-depth analysis of a nationally representative cohort. J Thorac Oncol, 2025, 20(6): 786-798.
9.	Liao H, Li X, Cheng Y, et al. A multiattribute decision-making framework for multidisciplinary lung cancer treatment considering expert willingness for opinion transformation. IEEE Trans Cybern, 2026, 56(1): 497-508.
10.	Ceresoli M, Braga M, Zanini N, et al. Enhanced perioperative care in emergency general surgery: the WSES position paper. World J Emerg Surg, 2023, 18: 47.
11.	Li J, Jiang Y, Wang J. Neoadjuvant immunotherapy for elderly patients with non-small-cell lung cancer: a case report and literature review. Ann Transl Med, 2021, 9(2): 182.
12.	D'Amours MF, Wu FTH, Theisen-Lauk O, et al. Surgically resectable nonsmall cell lung cancer: a contemporary approach. Eur Respir J, 2024, 64(2): 2400332.
13.	Bonanno L, Attili I, Pavan A, et al. Treatment strategies for locally advanced non-small cell lung cancer in elderly patients: translating scientific evidence into clinical practice. Crit Rev Oncol Hematol, 2021, 163: 103378.
14.	Zietlow KE, Wong S, Heflin MT, et al. Geriatric preoperative optimization: a review. Am J Med, 2022, 135(1): 39-48.
15.	Xu J, Ni H, Zhan H, et al. Efficacy of digital therapeutics for perioperative management in patients with lung cancer: a randomized controlled trial. BMC Med, 2025, 23(1): 186.
16.	Liu J, Ren Q, Cai Y, et al. Concerned issues and controversies in perioperative immunotherapy for resectable non-small cell lung cancer. Front Immunol, 2025, 16: 1704226.
17.	Catania C, Proto C, Bennati C, et al. Navigating chemotherapy and immunotherapy in early-stage lung cancer: a critical review and statements from INTERACTION group. Crit Rev Oncol Hematol, 2025, 208: 104633.
18.	Warkentin MT, Tammem?gi MC, Vakil E, et al. Brief report: evaluating early stage lung cancer survival patterns in patients at the upper age limit for lung cancer screening. J Thorac Oncol, 2025, 20(4): 507-512.
19.	Seder CW, Chang SC, Towe CW, et al. Anatomic lung resection is associated with improved survival compared with wedge resection for stage IA (≤2 cm) NSCLC. J Thorac Oncol, 2025, 20(8): 1075-1085.
20.	Lin H, Peng Z, Zhou K, et al. Differential efficacy of segmentectomy and wedge resection in sublobar resection compared to lobectomy for solid-dominant stage IA lung cancer: a systematic review and meta-analysis. Int J Surg, 2024, 110(2): 1159-1171.
21.	Liu C, Yang Z, Li Y, et al. Intentional wedge resection versus segmentectomy for ≤2 cm ground-glass-opacity-dominant non-small cell lung cancer: a real-world study using inverse probability of treatment weighting. Int J Surg, 2024, 110(7): 4231-4239.
22.	Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet, 2022, 399(10335): 1607-1617.
23.	Hattori A, Suzuki K, Takamochi K, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer with radiologically pure-solid appearance in Japan (JCOG0802/WJOG4607L): a post-hoc supplemental analysis of a multicentre, open-label, phase 3 trial. Lancet Respir Med, 2024, 12(2): 105-116.
24.	Isaka T, Ito H, Yokose T, et al. Long-term changes in psoas muscle mass after lobectomy and segmentectomy for early-stage lung cancer. J Cachexia Sarcopenia Muscle, 2023, 14(6): 2540-2549.
25.	Isaka T, Nagashima T, Washimi K, et al. Comparison of the changes in visceral adipose tissue after lobectomy and segmentectomy for patients with early-stage lung cancer. J Cachexia Sarcopenia Muscle, 2025, 16(2): e13751.
26.	Xu B, Chen Z, Liu D, et al. Comparison of outcomes between ablation and lobectomy in stage IA non-small cell lung cancer: a retrospective multicenter study. Respirology, 2025, 30(12): 1192-1201.
27.	Xu B, Huang D, Liu D, et al. Ablation versus sublobar resection for stageⅠA non-small cell lung cancer: a multicenter retrospective cohort study using a deep learning model in the ablation group. Int J Surg, 2025, 112(4): 10000-10009.
28.	Sang J, Ye X. Potential biomarkers for predicting immune response and outcomes in lung cancer patients undergoing thermal ablation. Front Immunol, 2023, 14: 1268331.
29.	Chen W, Wu Y, Luo J, et al. A synergistic 3D-printed collar transforms radiofrequency ablation into potent thermal immunotherapy for lung cancer. Adv Mater, 2025, 37(47): e02375.
30.	Zhi X, Xing Z, Luo L, et al. Cryoablation activates the cGAS–STING-CXCL10 axis in macrophages to enhance anti-tumor immunity in NSCLC. Adv Sci, 2026: e21931.
31.	Hirpara DH, Kidane B, Louie AV, et al. Long-term dependency in older adults after surgery or stereotactic body radiation therapy for stage I non-small cell lung cancer. Ann Surg, 2023, 278(2): e368-e376.
32.	Thompson LL, Amin PM, Shah S, et al. Associations between G8 geriatric screening score, Charlson comorbidity index, AI-based age phenotype, and overall survival in older adults with stageⅠ-Ⅱ non-small cell lung cancer. Int J Radiat Oncol Biol Phys, 2025, 123(5): 1295-1305.
33.	Xing T, Gao Q, Zhu H, et al. A single-center, retrospective study-spring-evaluating the efficacy and safety of recombinant human vascular endothelial inhibitor combined with anti-PD-1 in elderly patients aged 80 and above with NSCLC. Front Immunol, 2024, 15: 1402018.
34.	Yang K, Wang L, Wang Z, et al. Neoadjuvant immunotherapy for lung cancer: current limitations and future prospects. Front Immunol, 2026, 17: 1752298.
35.	Yao J, Li S, Bai L, et al. Efficacy and safety of immune checkpoint inhibitors in elderly patients with advanced non-small cell lung cancer: a systematic review and meta-analysis. EClinicalMedicine, 2025, 81: 103081.
36.	Shen J, Gu L, Qi Y, et al. Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer. Front Immunol, 2023, 14: 1268251.
37.	Wu Y, Verma V, Gay CM, et al. Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: a systematic review and meta-analysis. Cancer, 2023, 129(13): 1969-1985.
38.	Zhou S, Liu Y, Liu K, et al. Comparison of neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable stage III non-small cell lung cancer: a real-world cohort study. Front Immunol, 2023, 14: 1343504.
39.	Wang Y, Li C, Wang Z, et al. Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review. BMC Med, 2022, 20(1): 426.
40.	Yang Z, Chen Y, Wang Y, et al. Pembrolizumab plus chemotherapy versus chemotherapy monotherapy as a first-line treatment in elderly patients (≥75 years old) with non-small-cell lung cancer. Front Immunol, 2022, 13: 807575.
41.	Haderk F, Chou YT, Cech L, et al. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. Nat Commun, 2024, 15(1): 3741.
42.	Wang N, Wang C, Wang X, et al. Immunosenescence in elderly patients with advanced non-small cell lung cancer: mechanisms and therapeutic implications. Biochim Biophys Acta Rev Cancer, 2026, 1881(3): 189587.
43.	Staaf J, Aine M, Nacer DF, et al. Molecular characteristics of lung adenocarcinoma with respect to patient age at diagnosis. Int J Cancer, 2023, 153(1): 197-209.
44.	Yang J, Li Y, Sun J, et al. An osimertinib-perfluorocarbon nanoemulsion with excellent targeted therapeutic efficacy in non-small cell lung cancer: achieving intratracheal and intravenous administration. ACS Nano, 2022, 16(8): 12590-12605.
45.	Li JW, Zheng G, Kaye FJ, et al. PROTAC therapy as a new targeted therapy for lung cancer. Mol Ther, 2023, 31(3): 647-656.
46.	Conroy SP, van Oppen JD. Are we measuring what matters to older people? Lancet Healthy Longev, 2023, 4(7): e354-e356.
47.	Komici K, Bencivenga L, Navani N, et al. Frailty in patients with lung cancer: a systematic review and meta-analysis. Chest, 2022, 162(2): 485-497.
48.	Guo K, Wang X, Lu X, et al. Effects of sarcopenia and frailty on postoperative recovery in elderly patients: a prospective cohort study. J Cachexia Sarcopenia Muscle, 2023, 14(6): 2642-2652.
49.	Daum N, Hoff L, Spies C, et al. Influence of frailty status on the incidence of intraoperative hypotensive events in elective surgery: Hypo-Frail, a single-centre retrospective cohort study. Br J Anaesth, 2025, 135(1): 40-47.
50.	Vizzacchi BA, Dettino ALA, Besen B, et al. Delirium during critical illness and subsequent change of treatment in patients with cancer: a mediation analysis. Crit Care Med, 2024, 52(1): 102-111.
51.	Zhou H, Liu F, Xu J, et al. Relationships of sarcopenia symptoms and dietary patterns with lung cancer risk: a prospective cohort study. Food Funct, 2025, 16(6): 2432-2443.
52.	Bartels F, Wandrey MM, Aigner A, et al. Association between neuronal autoantibodies and cognitive impairment in patients with lung cancer. JAMA Oncol, 2021, 7(9): 1302-1310.
53.	Kiss N, Curtis A. Current insights in nutrition assessment and intervention for malnutrition or muscle loss in people with lung cancer: a narrative review. Adv Nutr, 2022, 13(6): 2420-2432.
54.	Hu X, Ma YN, Karako K, et al. Comprehensive assessment and treatment strategies for dysphagia in the elderly population: current status and prospects. Biosci Trends, 2024, 18(2): 116-126.
55.	Bauer JM, Pattwell M, Barazzoni R, et al. Systematic nutritional screening and assessment in older patients: rationale for its integration into oncology practice. Eur J Cancer, 2024, 209: 114237.
56.	Zupo R, Castellana F, Guerra V, et al. Associations between nutritional frailty and 8-year all-cause mortality in older adults: the Salus in Apulia study. J Intern Med, 2021, 290(5): 1071-1082.
57.	Abeywickrama HM, Uchiyama M, Sumiyoshi T, et al. The role of zinc on nutritional status, sarcopenia, and frailty in older adults: a scoping review. Nutr Rev, 2024, 82(7): 988-1011.
58.	Low CE, Pillay RM, Teo FJJ, et al. Educational interventions to reduce depression and anxiety in older adults with cancer in the community: a systematic review, meta-analysis and meta-regression of randomised controlled trials. Age Ageing, 2024, 53(6): afae111.
59.	Borg M, L?kke A, Ibsen R, et al. Four decades of lung cancer: trends in comorbidities and causes of death in a nationwide Danish cohort. Eur J Cancer, 2025, 218: 115303.
60.	Ioffe D, Bhatia-Patel SC, Gandhi S, et al. Cardiovascular concerns, cancer treatment, and biological and chronological aging in cancer: JACC family series. JACC CardioOncol, 2024, 6(2): 143-158.
61.	El-Rayes M, Nardi Agmon I, Yu C, et al. Lung cancer and cardiovascular disease: common pathophysiology and treatment-emergent toxicity. JACC CardioOncol, 2025, 7(4): 325-344.
62.	Larsen JR, Zheng C, La J, et al. Multimorbidity and its impact in older U. S. veterans newly treated for advanced non–small cell lung cancer. Ann Am Thorac Soc, 2025, 22(4): 598-608.
63.	Kaneko H, Yano Y, Lee H, et al. Blood pressure classification using the 2017 ACC/AHA guideline and heart failure in patients with cancer. J Clin Oncol, 2023, 41(5): 980-990.
64.	Bloom MW, Vo JB, Rodgers JE, et al. Cardio-oncology and heart failure: a scientific statement from the Heart Failure Society of America. J Card Fail, 2025, 31(2): 415-455.
65.	Sasaki YM, Xu T, Koutroumpakis S, et al. Comorbidities and their impact on treatment tolerance and outcome in elderly NSCLC patients treated with concurrent chemoradiation using proton or photon followed by immunotherapy. Int J Radiat Oncol Biol Phys, 2023, 117(2 Suppl): e54-e55.
66.	Fanizza JD, Moghaddam AS, Atrash A. Are patient factors associated with adverse perioperative outcomes in GLP-1 receptor agonist users? a retrospective cohort study. J Clin Anesth, 2026, 111: 112192.
67.	Chen L, Song D, Hou S, et al. The impact of comorbid COPD on survival outcomes in lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Front Immunol, 2025, 16: 1627557.
68.	Silvestris N, Franchina T, Gallo M, et al. Diabetes management in cancer patients: an Italian association of medical oncology, Italian association of medical diabetologists, Italian Society of Diabetology, Italian Society of Endocrinology and Italian Society of Pharmacology multidisciplinary consensus position paper. ESMO Open, 2023, 8(6): 102062.
69.	宋宇豪, 田文鑫, 李東航, 等. 老年肺癌患者圍術期心肺并發癥的早期識別與干預策略. 中國胸心血管外科臨床雜志, 2025, 32(9): 1-8.Song YH, Tian WX, Li DH, et al. Early identification and intervention strategies for perioperative cardiopulmonary complications in elderly patients with lung cancer. Chin J Clin Thorac Cardiovasc Surg, 2025, 32(9): 1-8.
70.	Ding Q, Ma F, Ma X, et al. Breathing exercises for patients with early-stage lung cancer: a meta-analysis. Syst Rev, 2024, 13(1): 243.
71.	Zheng Y, Mao M, Li F, et al. Effects of enhanced recovery after surgery plus pulmonary rehabilitation on complications after video-assisted lung cancer surgery: a multicentre randomised controlled trial. Thorax, 2023, 78(6): 574-586.
72.	Li P, Gao S, Wang Y, et al. Utilising intraoperative respiratory dynamic features for developing and validating an explainable machine learning model for postoperative pulmonary complications. Br J Anaesth, 2024, 132(6): 1315-1326.
73.	Zeng C, Lagier D, Lee JW, et al. Perioperative pulmonary atelectasis: partⅠ. Biology and mechanisms. Anesthesiology, 2022, 136(1): 181-205.
74.	Lagier D, Zeng C, Fernandez-Bustamante A, et al. Perioperative pulmonary atelectasis: part Ⅱ. Clinical implications. Anesthesiology, 2022, 136(1): 206-236.
75.	Wang W, Liu K, Huang C, et al. Pulmonary complications with individualised vs. fixed positive end-expiratory pressure in older patients recovering from lung cancer surgery: a randomised trial. Anaesthesia, 2026: 70165.
76.	Elfeky A, Chen YF, Grove A, et al. Perioperative oxygen therapy: an overview of systematic reviews and meta-analyses. Br J Anaesth, 2025, 135(5): 1456-1476.
77.	Boster JM, Goertzen M, Sarkiss M, et al. Superiority of lateral decubitus strategy in preventing atelectasis from obscuring targets during robotic bronchoscopy: lateral decubitus strategy vs ventilatory strategy to prevent atelectasis trial. Chest, 2026, 169(4): 1124-1134.
78.	Abbott M, Pereira SM, Sanders N, et al. Weaning from mechanical ventilation in the operating room: a systematic review. Br J Anaesth, 2024, 133(2): 424-436.
79.	Pinezich M, Mir M, Reimer J, et al. Sound-guided assessment and localization of pulmonary air leak. Bioeng Transl Med, 2022, 8(1): e10322.
80.	Wong MSH, Naruka V, De Sousa P, et al. Clinical efficacy of surgical sealants after pulmonary resection: an individual patient data meta-analysis of randomized controlled trials. Int J Surg, 2025, 112(3): 8314-8322.
81.	Tran TN, Lee S, Kim HJ, et al. Treatment-related cardiovascular events in patients with non-small cell lung cancer: evidence from real-world data with a competing risks approach. Cancer, 2023, 130(8): 1303-1315.
82.	Loudovici-Krug D, André L, Blumensaat HP, et al. Physical prehabilitation for older patients with cancer before complex medical-surgical interventions: an umbrella review. Aging Dis, 2024, 16(5): 2859-2869.
83.	Brat K, Sova M, Homolka P, et al. Multimodal prehabilitation before lung resection surgery: a multicentre randomised controlled trial. Br J Anaesth, 2025, 135(1): 188-196.
84.	Dent E, Wright ORL, Woo J, et al. Malnutrition in older adults. Lancet, 2023, 401(10380): 951-966.
85.	Boccardi V, Marano L. Improving geriatric outcomes through nutritional and immunonutritional strategies: focus on surgical setting by a comprehensive evidence review. Ageing Res Rev, 2024, 96: 102272.
86.	Ferreira V, Lawson C, Carli F, et al. Feasibility of a novel mixed-nutrient supplement in a multimodal prehabilitation intervention for lung cancer patients awaiting surgery: a randomized controlled pilot trial. Int J Surg, 2021, 93: 106079.
87.	Gravier FE, Smondack P, Prieur G, et al. Effects of exercise training in people with non-small cell lung cancer before lung resection: a systematic review and meta-analysis. Thorax, 2022, 77(5): 486-496.
88.	Ligibel JA, Bohlke K, May AM, et al. Exercise, diet, and weight management during cancer treatment: ASCO guideline. J Clin Oncol, 2022, 40(22): 2491-2507.
89.	Chen X, Li Z, Zhang J. A novel approach to cancer rehabilitation: assessing the influence of exercise intervention on postoperative recovery and survival rates. Int J Surg, 2025, 111(5): 3373-3385.
90.	Heiden BT, Eaton DB Jr, Chang SH, et al. Assessment of duration of smoking cessation prior to surgical treatment of non-small cell lung cancer. Ann Surg, 2023, 277(4): e933-e940.
91.	Yuan J, Sun Y, Xu F, et al. Cost-effectiveness of lung cancer screening combined with nurse-led smoking cessation intervention: a population-based microsimulation study. Int J Nurs Stud, 2022, 134: 104319.
92.	Kurtti A, Iivanainen S, Kaarteenaho R, et al. Effect of lung cancer screening, smoking cessation, and cessation smartphone app to health-related quality of life among heavy smokers: randomized controlled trial. J Med Internet Res, 2026, 28: e81687.
93.	Han B, Einstein EB, Compton WM. Patterns and characteristics of nicotine dependence among adults with cigarette use in the US, 2006-2019. JAMA Netw Open, 2023, 6(6): e2319602.
94.	McCaffrey N, Higgins J, Greenhalgh E, et al. A systematic review of economic evaluations of preoperative smoking cessation for preventing surgical complications. Int J Surg, 2022, 104: 106742.
95.	Evison M, Naylor R, Malcolm R, et al. Health economic model to evaluate the cost-effectiveness of smoking cessation services integrated within lung cancer screening in the United Kingdom. Thorax, 2026: 222815.
96.	Qin X, Cheng B, Ma S, et al. Tandospirone augments cisplatin treatment by lowering cholesterol and managing distress in NSCLC patients. NPJ Digit Med, 2025, 8(1): 663.
97.	Zhang Q, Tang L, Chen H, et al. Psychological outcomes of the systematic interventions based on the stress-induced situation, affective, bodily, and cognitive reactions framework for patients with lung cancer: a randomized clinical trial. Int J Nurs Stud, 2023, 146: 104566.
98.	Li J, Li C, Puts M, et al. Effectiveness of mindfulness-based interventions on anxiety, depression, and fatigue in people with lung cancer: a systematic review and meta-analysis. Int J Nurs Stud, 2023, 140: 104447.
99.	Soong RY, Low CE, Ong V, et al. Exercise interventions for depression, anxiety, and quality of life in older adults with cancer: a systematic review and meta-analysis. JAMA Netw Open, 2025, 8(2): e2457859.
100.	Ma R, Leung JM. Managing geriatric syndromes in perioperative care - implications for anesthesia practice: a narrative review. J Clin Anesth, 2025, 107: 112023.
101.	Herzog SM, Ortolano LC, Brenner W, et al. Biomarkers in blood and saliva to screen fragile patients with solid tumors: a systematic review of the literature. Crit Rev Oncol Hematol, 2025, 216: 104939.
102.	Marcantonio E, Ngo L, O'Connor M, et al. 3D-CAM: derivation and validation of a 3-minute diagnostic interview for CAM-defined delirium. Ann Intern Med, 2014, 161(8): 554-561.
103.	Alici Y, Breitbart W. Memorial delirium assessment scale. In: Stolerman IP, ed. Encyclopedia of psychopharmacology. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010: 753-753.
104.	Malmstrom TK, Miller DK, Simonsick EM, et al. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle, 2016, 7(1): 28-36.
105.	Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc, 2020, 21(3): 300-307.
106.	Lian Y, Tian Y. The clinical study of the effect of WBRT on cognitive function of patients with brain metastasis of lung cancer. Int J Radiat Oncol Biol Phys, 2021, 111(3 Suppl): e572.
107.	Yan E, Alhamdah Y, Campbell S, et al. The utility of the ascertain dementia eight-item questionnaire (AD8) and Mini-Cog in detecting cognitive impairment in older surgical patients - the Detect CI study. J Clin Anesth, 2025, 106: 111940.
108.	Cao J, Xiang F, Zhang J, et al. Knowledge, attitudes, and practices of lung cancer patients regarding nutritional management during chemotherapy. Front Nutr, 2026, 13: 1678612.
109.	Feng L, Chu Z, Quan X, et al. Malnutrition is positively associated with cognitive decline in centenarians and oldest-old adults: a cross-sectional study. EClinicalMedicine, 2022, 47: 101336.
110.	Doan TN, Ho WC, Wang LH, et al. Prevalence and methods for assessment of oropharyngeal dysphagia in older adults: a systematic review and meta-analysis. J Clin Med, 2022, 11(9): 2605.
111.	Steele CM, Bayley MT, Bohn MK, et al. Reference values for videofluoroscopic measures of swallowing: an update. J Speech Lang Hear Res, 2023, 66(10): 3804-3824.
112.	Jaghbeer M, Sutt AL, Bergstr?m L. Dysphagia management and cervical auscultation: reliability and validity against FEES. Dysphagia, 2023, 38(1): 305-314.
113.	Chen A, An E, Yan E, et al. Prevalence of preoperative depression and adverse outcomes in older patients undergoing elective surgery: a systematic review and meta-analysis. J Clin Anesth, 2024, 97: 111532.
114.	Mantzari A, Botella-Juan L, Yadav P, et al. Cross-cultural validity of the generalized anxiety disorder 7-item scale (GAD-7): a systematic review and standardized assessment. Epidemiol Psychiatr Sci, 2026, 35: e24.
115.	Benderra MA, Serrano AG, Paillaud E, et al. Prognostic value of comorbidities in older patients with cancer: the ELCAPA cohort study. ESMO Open, 2023, 8(5): 101831.
116.	Gendarme S, Irajizad E, Long JP, et al. Impact of comorbidities on the mortality benefits of lung cancer screening: a post-hoc analysis of the PLCO and NLST trials. J Thorac Oncol, 2025, 20(5): 565-576.
117.	Abravan A, Faivre-Finn C, Gomes F, et al. Comorbidity in patients with cancer treated at The Christie. Br J Cancer, 2024, 131(8): 1279-1289.
118.	Chen W, Altshuler RD, Daschner P, et al. Older adults with cancer and common comorbidities-challenges and opportunities in improving their cancer treatment outcomes. J Natl Cancer Inst, 2024, 116(11): 1730-1738.
119.	García-Pardo M, Chang A, Schmid S, et al. Respiratory and cardiometabolic comorbidities and stagesⅠto Ⅲ NSCLC survival: a pooled analysis from the International Lung Cancer Consortium. J Thorac Oncol, 2023, 18(3): 313-323.
120.	Ayada G, Edel Y, Burg A, et al. Multidisciplinary team led by internists improves diabetic foot ulceration outcomes a before-after retrospective study. Eur J Intern Med, 2021, 94: 64-68.
121.	An Q, Li Y, Shi J, et al. Promoting postoperative recovery in older adult surgical patients: a randomized controlled trial of MDT-based perioperative comprehensive nutritional management model. Front Nutr, 2025, 12: 1684807.
122.	Herledan C, Toulemonde A, Clairet AL, et al. Enhancing collaboration between geriatricians, oncologists, and pharmacists to optimize medication therapy in older adults with cancer: a position paper from SOFOG-SFPO. Crit Rev Oncol Hematol, 2023, 190: 104117.
123.	Basety S, Gudepu R, Velidandi A. Artificial intelligence in lung cancer: a narrative review of recent advances in diagnosis, biomarker discovery, and drug development. Pharmaceutics, 2026, 18(2): 491.
124.	Huang S, Yang J, Shen N, et al. Artificial intelligence in lung cancer diagnosis and prognosis: current application and future perspective. Semin Cancer Biol, 2023, 89: 30-37.
125.	Shen J, Feng S, Zhang P, et al. Evaluating generative AI models for explainable pathological feature extraction in lung adenocarcinoma: grading assessment and prognostic model construction. Int J Surg, 2025, 111(7): 4252-4262.
126.	Zhu E, Muneer A, Zhang J, et al. Progress and challenges of artificial intelligence in lung cancer clinical translation. NPJ Precis Oncol, 2025, 9(1): 210.
127.	Bonci EA, Bandura A, Dooley A, et al. Artificial intelligence in NSCLC management for revolutionizing diagnosis, prognosis, and treatment optimization: a systematic review. Crit Rev Oncol Hematol, 2025, 216: 104929.
128.	Zhou D, Liu J, Zhang C, et al. Elevated serum total immunoglobulin E is associated with an increased risk of lung cancer: a retrospective study. Front Immunol, 2025, 16: 1637803.
129.	Chen Y, Xing H, Yang X, et al. Patient-derived malignant effusion organoids guide tailored therapy and dissect third-generation EGFR-tyrosine kinase inhibitor resistance mechanisms in lung cancer. Cancer Lett, 2026, 645: 218356.
130.	Zhou H, Zheng Z, Fan C, et al. Mechanisms and strategies of immunosenescence effects on non-small cell lung cancer (NSCLC) treatment: a comprehensive analysis and future directions. Semin Cancer Biol, 2025, 109: 44-66.
131.	Wang R, Zheng J, Guo W, et al. Integrating a multimodal digital device for continuous perioperative monitoring in patients with lung cancer undergoing thoracic surgery: development and usability study. JMIR Mhealth Uhealth, 2025, 13: e69512.
132.	Lee J, Kong S, Shin S, et al. Wearable device-based intervention for promoting patient physical activity after lung cancer surgery: a nonrandomized clinical trial. JAMA Netw Open, 2024, 7(9): e2434180.
133.	Kvedar JC, Mittermaier M, Pritzker J. The industry impact of the American Medical Association’s Digital Medicine Payment Advisory Group (DMPAG). NPJ Digit Med, 2022, 5(1): 193.
134.	Kim A, Chatterjee M, Iansavitchene A, et al. Artificial intelligence for electrocardiographic diagnosis of perioperative myocardial ischaemia: a scoping review. Br J Anaesth, 2025, 135(3): 561-570.

1. Cao Y, Tian Y, Li L. Perioperative immune checkpoint inhibitors in elderly patients with resectable NSCLC: a systematic review and meta-analysis. Front Oncol, 2025, 15: 1589846.
2. Qi J, Li M, Wang L, et al. National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data. Lancet Public Health, 2023, 8(12): e943-e955.
3. Gros L, Yip R, Ma W, et al. Surgical outcomes and quality of life in octogenarians with early-stage non-small cell lung cancer: a prospective cohort study. Lancet Reg Health Am, 2026, 56: 101428.
4. Shi S, Yao J, Fu C, et al. The heterogeneous nutritional status trajectory and its predictors in elderly patients undergoing lung cancer surgery: a prospective cohort study. Front Nutr, 2026, 13: 1747612.
5. Azem K, Fein S, Zribi B, et al. Additive value of superficial parasternal intercostal plane block and serratus anterior plane block in lung transplantation surgery: a retrospective exploratory study. Reg Anesth Pain Med, 2024: 105137.
6. Li D, Sun CL, Kim H, et al. Geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults with cancer: a randomized controlled trial. J Clin Oncol, 2021, 7(11): e214158.
7. Mohile SG, Mohamed MR, Xu H, et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet, 2021, 398(10314): 1894-1904.
8. Bostock IC, Fox AH, Ward RC, et al. Outcomes after surgical management of early-stage lung cancer in octogenarians: an in-depth analysis of a nationally representative cohort. J Thorac Oncol, 2025, 20(6): 786-798.
9. Liao H, Li X, Cheng Y, et al. A multiattribute decision-making framework for multidisciplinary lung cancer treatment considering expert willingness for opinion transformation. IEEE Trans Cybern, 2026, 56(1): 497-508.
10. Ceresoli M, Braga M, Zanini N, et al. Enhanced perioperative care in emergency general surgery: the WSES position paper. World J Emerg Surg, 2023, 18: 47.
11. Li J, Jiang Y, Wang J. Neoadjuvant immunotherapy for elderly patients with non-small-cell lung cancer: a case report and literature review. Ann Transl Med, 2021, 9(2): 182.
12. D'Amours MF, Wu FTH, Theisen-Lauk O, et al. Surgically resectable nonsmall cell lung cancer: a contemporary approach. Eur Respir J, 2024, 64(2): 2400332.
13. Bonanno L, Attili I, Pavan A, et al. Treatment strategies for locally advanced non-small cell lung cancer in elderly patients: translating scientific evidence into clinical practice. Crit Rev Oncol Hematol, 2021, 163: 103378.
14. Zietlow KE, Wong S, Heflin MT, et al. Geriatric preoperative optimization: a review. Am J Med, 2022, 135(1): 39-48.
15. Xu J, Ni H, Zhan H, et al. Efficacy of digital therapeutics for perioperative management in patients with lung cancer: a randomized controlled trial. BMC Med, 2025, 23(1): 186.
16. Liu J, Ren Q, Cai Y, et al. Concerned issues and controversies in perioperative immunotherapy for resectable non-small cell lung cancer. Front Immunol, 2025, 16: 1704226.
17. Catania C, Proto C, Bennati C, et al. Navigating chemotherapy and immunotherapy in early-stage lung cancer: a critical review and statements from INTERACTION group. Crit Rev Oncol Hematol, 2025, 208: 104633.
18. Warkentin MT, Tammem?gi MC, Vakil E, et al. Brief report: evaluating early stage lung cancer survival patterns in patients at the upper age limit for lung cancer screening. J Thorac Oncol, 2025, 20(4): 507-512.
19. Seder CW, Chang SC, Towe CW, et al. Anatomic lung resection is associated with improved survival compared with wedge resection for stage IA (≤2 cm) NSCLC. J Thorac Oncol, 2025, 20(8): 1075-1085.
20. Lin H, Peng Z, Zhou K, et al. Differential efficacy of segmentectomy and wedge resection in sublobar resection compared to lobectomy for solid-dominant stage IA lung cancer: a systematic review and meta-analysis. Int J Surg, 2024, 110(2): 1159-1171.
21. Liu C, Yang Z, Li Y, et al. Intentional wedge resection versus segmentectomy for ≤2 cm ground-glass-opacity-dominant non-small cell lung cancer: a real-world study using inverse probability of treatment weighting. Int J Surg, 2024, 110(7): 4231-4239.
22. Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet, 2022, 399(10335): 1607-1617.
23. Hattori A, Suzuki K, Takamochi K, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer with radiologically pure-solid appearance in Japan (JCOG0802/WJOG4607L): a post-hoc supplemental analysis of a multicentre, open-label, phase 3 trial. Lancet Respir Med, 2024, 12(2): 105-116.
24. Isaka T, Ito H, Yokose T, et al. Long-term changes in psoas muscle mass after lobectomy and segmentectomy for early-stage lung cancer. J Cachexia Sarcopenia Muscle, 2023, 14(6): 2540-2549.
25. Isaka T, Nagashima T, Washimi K, et al. Comparison of the changes in visceral adipose tissue after lobectomy and segmentectomy for patients with early-stage lung cancer. J Cachexia Sarcopenia Muscle, 2025, 16(2): e13751.
26. Xu B, Chen Z, Liu D, et al. Comparison of outcomes between ablation and lobectomy in stage IA non-small cell lung cancer: a retrospective multicenter study. Respirology, 2025, 30(12): 1192-1201.
27. Xu B, Huang D, Liu D, et al. Ablation versus sublobar resection for stageⅠA non-small cell lung cancer: a multicenter retrospective cohort study using a deep learning model in the ablation group. Int J Surg, 2025, 112(4): 10000-10009.
28. Sang J, Ye X. Potential biomarkers for predicting immune response and outcomes in lung cancer patients undergoing thermal ablation. Front Immunol, 2023, 14: 1268331.
29. Chen W, Wu Y, Luo J, et al. A synergistic 3D-printed collar transforms radiofrequency ablation into potent thermal immunotherapy for lung cancer. Adv Mater, 2025, 37(47): e02375.
30. Zhi X, Xing Z, Luo L, et al. Cryoablation activates the cGAS–STING-CXCL10 axis in macrophages to enhance anti-tumor immunity in NSCLC. Adv Sci, 2026: e21931.
31. Hirpara DH, Kidane B, Louie AV, et al. Long-term dependency in older adults after surgery or stereotactic body radiation therapy for stage I non-small cell lung cancer. Ann Surg, 2023, 278(2): e368-e376.
32. Thompson LL, Amin PM, Shah S, et al. Associations between G8 geriatric screening score, Charlson comorbidity index, AI-based age phenotype, and overall survival in older adults with stageⅠ-Ⅱ non-small cell lung cancer. Int J Radiat Oncol Biol Phys, 2025, 123(5): 1295-1305.
33. Xing T, Gao Q, Zhu H, et al. A single-center, retrospective study-spring-evaluating the efficacy and safety of recombinant human vascular endothelial inhibitor combined with anti-PD-1 in elderly patients aged 80 and above with NSCLC. Front Immunol, 2024, 15: 1402018.
34. Yang K, Wang L, Wang Z, et al. Neoadjuvant immunotherapy for lung cancer: current limitations and future prospects. Front Immunol, 2026, 17: 1752298.
35. Yao J, Li S, Bai L, et al. Efficacy and safety of immune checkpoint inhibitors in elderly patients with advanced non-small cell lung cancer: a systematic review and meta-analysis. EClinicalMedicine, 2025, 81: 103081.
36. Shen J, Gu L, Qi Y, et al. Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer. Front Immunol, 2023, 14: 1268251.
37. Wu Y, Verma V, Gay CM, et al. Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: a systematic review and meta-analysis. Cancer, 2023, 129(13): 1969-1985.
38. Zhou S, Liu Y, Liu K, et al. Comparison of neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable stage III non-small cell lung cancer: a real-world cohort study. Front Immunol, 2023, 14: 1343504.
39. Wang Y, Li C, Wang Z, et al. Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review. BMC Med, 2022, 20(1): 426.
40. Yang Z, Chen Y, Wang Y, et al. Pembrolizumab plus chemotherapy versus chemotherapy monotherapy as a first-line treatment in elderly patients (≥75 years old) with non-small-cell lung cancer. Front Immunol, 2022, 13: 807575.
41. Haderk F, Chou YT, Cech L, et al. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. Nat Commun, 2024, 15(1): 3741.
42. Wang N, Wang C, Wang X, et al. Immunosenescence in elderly patients with advanced non-small cell lung cancer: mechanisms and therapeutic implications. Biochim Biophys Acta Rev Cancer, 2026, 1881(3): 189587.
43. Staaf J, Aine M, Nacer DF, et al. Molecular characteristics of lung adenocarcinoma with respect to patient age at diagnosis. Int J Cancer, 2023, 153(1): 197-209.
44. Yang J, Li Y, Sun J, et al. An osimertinib-perfluorocarbon nanoemulsion with excellent targeted therapeutic efficacy in non-small cell lung cancer: achieving intratracheal and intravenous administration. ACS Nano, 2022, 16(8): 12590-12605.
45. Li JW, Zheng G, Kaye FJ, et al. PROTAC therapy as a new targeted therapy for lung cancer. Mol Ther, 2023, 31(3): 647-656.
46. Conroy SP, van Oppen JD. Are we measuring what matters to older people? Lancet Healthy Longev, 2023, 4(7): e354-e356.
47. Komici K, Bencivenga L, Navani N, et al. Frailty in patients with lung cancer: a systematic review and meta-analysis. Chest, 2022, 162(2): 485-497.
48. Guo K, Wang X, Lu X, et al. Effects of sarcopenia and frailty on postoperative recovery in elderly patients: a prospective cohort study. J Cachexia Sarcopenia Muscle, 2023, 14(6): 2642-2652.
49. Daum N, Hoff L, Spies C, et al. Influence of frailty status on the incidence of intraoperative hypotensive events in elective surgery: Hypo-Frail, a single-centre retrospective cohort study. Br J Anaesth, 2025, 135(1): 40-47.
50. Vizzacchi BA, Dettino ALA, Besen B, et al. Delirium during critical illness and subsequent change of treatment in patients with cancer: a mediation analysis. Crit Care Med, 2024, 52(1): 102-111.
51. Zhou H, Liu F, Xu J, et al. Relationships of sarcopenia symptoms and dietary patterns with lung cancer risk: a prospective cohort study. Food Funct, 2025, 16(6): 2432-2443.
52. Bartels F, Wandrey MM, Aigner A, et al. Association between neuronal autoantibodies and cognitive impairment in patients with lung cancer. JAMA Oncol, 2021, 7(9): 1302-1310.
53. Kiss N, Curtis A. Current insights in nutrition assessment and intervention for malnutrition or muscle loss in people with lung cancer: a narrative review. Adv Nutr, 2022, 13(6): 2420-2432.
54. Hu X, Ma YN, Karako K, et al. Comprehensive assessment and treatment strategies for dysphagia in the elderly population: current status and prospects. Biosci Trends, 2024, 18(2): 116-126.
55. Bauer JM, Pattwell M, Barazzoni R, et al. Systematic nutritional screening and assessment in older patients: rationale for its integration into oncology practice. Eur J Cancer, 2024, 209: 114237.
56. Zupo R, Castellana F, Guerra V, et al. Associations between nutritional frailty and 8-year all-cause mortality in older adults: the Salus in Apulia study. J Intern Med, 2021, 290(5): 1071-1082.
57. Abeywickrama HM, Uchiyama M, Sumiyoshi T, et al. The role of zinc on nutritional status, sarcopenia, and frailty in older adults: a scoping review. Nutr Rev, 2024, 82(7): 988-1011.
58. Low CE, Pillay RM, Teo FJJ, et al. Educational interventions to reduce depression and anxiety in older adults with cancer in the community: a systematic review, meta-analysis and meta-regression of randomised controlled trials. Age Ageing, 2024, 53(6): afae111.
59. Borg M, L?kke A, Ibsen R, et al. Four decades of lung cancer: trends in comorbidities and causes of death in a nationwide Danish cohort. Eur J Cancer, 2025, 218: 115303.
60. Ioffe D, Bhatia-Patel SC, Gandhi S, et al. Cardiovascular concerns, cancer treatment, and biological and chronological aging in cancer: JACC family series. JACC CardioOncol, 2024, 6(2): 143-158.
61. El-Rayes M, Nardi Agmon I, Yu C, et al. Lung cancer and cardiovascular disease: common pathophysiology and treatment-emergent toxicity. JACC CardioOncol, 2025, 7(4): 325-344.
62. Larsen JR, Zheng C, La J, et al. Multimorbidity and its impact in older U. S. veterans newly treated for advanced non–small cell lung cancer. Ann Am Thorac Soc, 2025, 22(4): 598-608.
63. Kaneko H, Yano Y, Lee H, et al. Blood pressure classification using the 2017 ACC/AHA guideline and heart failure in patients with cancer. J Clin Oncol, 2023, 41(5): 980-990.
64. Bloom MW, Vo JB, Rodgers JE, et al. Cardio-oncology and heart failure: a scientific statement from the Heart Failure Society of America. J Card Fail, 2025, 31(2): 415-455.
65. Sasaki YM, Xu T, Koutroumpakis S, et al. Comorbidities and their impact on treatment tolerance and outcome in elderly NSCLC patients treated with concurrent chemoradiation using proton or photon followed by immunotherapy. Int J Radiat Oncol Biol Phys, 2023, 117(2 Suppl): e54-e55.
66. Fanizza JD, Moghaddam AS, Atrash A. Are patient factors associated with adverse perioperative outcomes in GLP-1 receptor agonist users? a retrospective cohort study. J Clin Anesth, 2026, 111: 112192.
67. Chen L, Song D, Hou S, et al. The impact of comorbid COPD on survival outcomes in lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Front Immunol, 2025, 16: 1627557.
68. Silvestris N, Franchina T, Gallo M, et al. Diabetes management in cancer patients: an Italian association of medical oncology, Italian association of medical diabetologists, Italian Society of Diabetology, Italian Society of Endocrinology and Italian Society of Pharmacology multidisciplinary consensus position paper. ESMO Open, 2023, 8(6): 102062.
69. 宋宇豪, 田文鑫, 李東航, 等. 老年肺癌患者圍術期心肺并發癥的早期識別與干預策略. 中國胸心血管外科臨床雜志, 2025, 32(9): 1-8.Song YH, Tian WX, Li DH, et al. Early identification and intervention strategies for perioperative cardiopulmonary complications in elderly patients with lung cancer. Chin J Clin Thorac Cardiovasc Surg, 2025, 32(9): 1-8.
70. Ding Q, Ma F, Ma X, et al. Breathing exercises for patients with early-stage lung cancer: a meta-analysis. Syst Rev, 2024, 13(1): 243.
71. Zheng Y, Mao M, Li F, et al. Effects of enhanced recovery after surgery plus pulmonary rehabilitation on complications after video-assisted lung cancer surgery: a multicentre randomised controlled trial. Thorax, 2023, 78(6): 574-586.
72. Li P, Gao S, Wang Y, et al. Utilising intraoperative respiratory dynamic features for developing and validating an explainable machine learning model for postoperative pulmonary complications. Br J Anaesth, 2024, 132(6): 1315-1326.
73. Zeng C, Lagier D, Lee JW, et al. Perioperative pulmonary atelectasis: partⅠ. Biology and mechanisms. Anesthesiology, 2022, 136(1): 181-205.
74. Lagier D, Zeng C, Fernandez-Bustamante A, et al. Perioperative pulmonary atelectasis: part Ⅱ. Clinical implications. Anesthesiology, 2022, 136(1): 206-236.
75. Wang W, Liu K, Huang C, et al. Pulmonary complications with individualised vs. fixed positive end-expiratory pressure in older patients recovering from lung cancer surgery: a randomised trial. Anaesthesia, 2026: 70165.
76. Elfeky A, Chen YF, Grove A, et al. Perioperative oxygen therapy: an overview of systematic reviews and meta-analyses. Br J Anaesth, 2025, 135(5): 1456-1476.
77. Boster JM, Goertzen M, Sarkiss M, et al. Superiority of lateral decubitus strategy in preventing atelectasis from obscuring targets during robotic bronchoscopy: lateral decubitus strategy vs ventilatory strategy to prevent atelectasis trial. Chest, 2026, 169(4): 1124-1134.
78. Abbott M, Pereira SM, Sanders N, et al. Weaning from mechanical ventilation in the operating room: a systematic review. Br J Anaesth, 2024, 133(2): 424-436.
79. Pinezich M, Mir M, Reimer J, et al. Sound-guided assessment and localization of pulmonary air leak. Bioeng Transl Med, 2022, 8(1): e10322.
80. Wong MSH, Naruka V, De Sousa P, et al. Clinical efficacy of surgical sealants after pulmonary resection: an individual patient data meta-analysis of randomized controlled trials. Int J Surg, 2025, 112(3): 8314-8322.
81. Tran TN, Lee S, Kim HJ, et al. Treatment-related cardiovascular events in patients with non-small cell lung cancer: evidence from real-world data with a competing risks approach. Cancer, 2023, 130(8): 1303-1315.
82. Loudovici-Krug D, André L, Blumensaat HP, et al. Physical prehabilitation for older patients with cancer before complex medical-surgical interventions: an umbrella review. Aging Dis, 2024, 16(5): 2859-2869.
83. Brat K, Sova M, Homolka P, et al. Multimodal prehabilitation before lung resection surgery: a multicentre randomised controlled trial. Br J Anaesth, 2025, 135(1): 188-196.
84. Dent E, Wright ORL, Woo J, et al. Malnutrition in older adults. Lancet, 2023, 401(10380): 951-966.
85. Boccardi V, Marano L. Improving geriatric outcomes through nutritional and immunonutritional strategies: focus on surgical setting by a comprehensive evidence review. Ageing Res Rev, 2024, 96: 102272.
86. Ferreira V, Lawson C, Carli F, et al. Feasibility of a novel mixed-nutrient supplement in a multimodal prehabilitation intervention for lung cancer patients awaiting surgery: a randomized controlled pilot trial. Int J Surg, 2021, 93: 106079.
87. Gravier FE, Smondack P, Prieur G, et al. Effects of exercise training in people with non-small cell lung cancer before lung resection: a systematic review and meta-analysis. Thorax, 2022, 77(5): 486-496.
88. Ligibel JA, Bohlke K, May AM, et al. Exercise, diet, and weight management during cancer treatment: ASCO guideline. J Clin Oncol, 2022, 40(22): 2491-2507.
89. Chen X, Li Z, Zhang J. A novel approach to cancer rehabilitation: assessing the influence of exercise intervention on postoperative recovery and survival rates. Int J Surg, 2025, 111(5): 3373-3385.
90. Heiden BT, Eaton DB Jr, Chang SH, et al. Assessment of duration of smoking cessation prior to surgical treatment of non-small cell lung cancer. Ann Surg, 2023, 277(4): e933-e940.
91. Yuan J, Sun Y, Xu F, et al. Cost-effectiveness of lung cancer screening combined with nurse-led smoking cessation intervention: a population-based microsimulation study. Int J Nurs Stud, 2022, 134: 104319.
92. Kurtti A, Iivanainen S, Kaarteenaho R, et al. Effect of lung cancer screening, smoking cessation, and cessation smartphone app to health-related quality of life among heavy smokers: randomized controlled trial. J Med Internet Res, 2026, 28: e81687.
93. Han B, Einstein EB, Compton WM. Patterns and characteristics of nicotine dependence among adults with cigarette use in the US, 2006-2019. JAMA Netw Open, 2023, 6(6): e2319602.
94. McCaffrey N, Higgins J, Greenhalgh E, et al. A systematic review of economic evaluations of preoperative smoking cessation for preventing surgical complications. Int J Surg, 2022, 104: 106742.
95. Evison M, Naylor R, Malcolm R, et al. Health economic model to evaluate the cost-effectiveness of smoking cessation services integrated within lung cancer screening in the United Kingdom. Thorax, 2026: 222815.
96. Qin X, Cheng B, Ma S, et al. Tandospirone augments cisplatin treatment by lowering cholesterol and managing distress in NSCLC patients. NPJ Digit Med, 2025, 8(1): 663.
97. Zhang Q, Tang L, Chen H, et al. Psychological outcomes of the systematic interventions based on the stress-induced situation, affective, bodily, and cognitive reactions framework for patients with lung cancer: a randomized clinical trial. Int J Nurs Stud, 2023, 146: 104566.
98. Li J, Li C, Puts M, et al. Effectiveness of mindfulness-based interventions on anxiety, depression, and fatigue in people with lung cancer: a systematic review and meta-analysis. Int J Nurs Stud, 2023, 140: 104447.
99. Soong RY, Low CE, Ong V, et al. Exercise interventions for depression, anxiety, and quality of life in older adults with cancer: a systematic review and meta-analysis. JAMA Netw Open, 2025, 8(2): e2457859.
100. Ma R, Leung JM. Managing geriatric syndromes in perioperative care - implications for anesthesia practice: a narrative review. J Clin Anesth, 2025, 107: 112023.
101. Herzog SM, Ortolano LC, Brenner W, et al. Biomarkers in blood and saliva to screen fragile patients with solid tumors: a systematic review of the literature. Crit Rev Oncol Hematol, 2025, 216: 104939.
102. Marcantonio E, Ngo L, O'Connor M, et al. 3D-CAM: derivation and validation of a 3-minute diagnostic interview for CAM-defined delirium. Ann Intern Med, 2014, 161(8): 554-561.
103. Alici Y, Breitbart W. Memorial delirium assessment scale. In: Stolerman IP, ed. Encyclopedia of psychopharmacology. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010: 753-753.
104. Malmstrom TK, Miller DK, Simonsick EM, et al. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle, 2016, 7(1): 28-36.
105. Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc, 2020, 21(3): 300-307.
106. Lian Y, Tian Y. The clinical study of the effect of WBRT on cognitive function of patients with brain metastasis of lung cancer. Int J Radiat Oncol Biol Phys, 2021, 111(3 Suppl): e572.
107. Yan E, Alhamdah Y, Campbell S, et al. The utility of the ascertain dementia eight-item questionnaire (AD8) and Mini-Cog in detecting cognitive impairment in older surgical patients - the Detect CI study. J Clin Anesth, 2025, 106: 111940.
108. Cao J, Xiang F, Zhang J, et al. Knowledge, attitudes, and practices of lung cancer patients regarding nutritional management during chemotherapy. Front Nutr, 2026, 13: 1678612.
109. Feng L, Chu Z, Quan X, et al. Malnutrition is positively associated with cognitive decline in centenarians and oldest-old adults: a cross-sectional study. EClinicalMedicine, 2022, 47: 101336.
110. Doan TN, Ho WC, Wang LH, et al. Prevalence and methods for assessment of oropharyngeal dysphagia in older adults: a systematic review and meta-analysis. J Clin Med, 2022, 11(9): 2605.
111. Steele CM, Bayley MT, Bohn MK, et al. Reference values for videofluoroscopic measures of swallowing: an update. J Speech Lang Hear Res, 2023, 66(10): 3804-3824.
112. Jaghbeer M, Sutt AL, Bergstr?m L. Dysphagia management and cervical auscultation: reliability and validity against FEES. Dysphagia, 2023, 38(1): 305-314.
113. Chen A, An E, Yan E, et al. Prevalence of preoperative depression and adverse outcomes in older patients undergoing elective surgery: a systematic review and meta-analysis. J Clin Anesth, 2024, 97: 111532.
114. Mantzari A, Botella-Juan L, Yadav P, et al. Cross-cultural validity of the generalized anxiety disorder 7-item scale (GAD-7): a systematic review and standardized assessment. Epidemiol Psychiatr Sci, 2026, 35: e24.
115. Benderra MA, Serrano AG, Paillaud E, et al. Prognostic value of comorbidities in older patients with cancer: the ELCAPA cohort study. ESMO Open, 2023, 8(5): 101831.
116. Gendarme S, Irajizad E, Long JP, et al. Impact of comorbidities on the mortality benefits of lung cancer screening: a post-hoc analysis of the PLCO and NLST trials. J Thorac Oncol, 2025, 20(5): 565-576.
117. Abravan A, Faivre-Finn C, Gomes F, et al. Comorbidity in patients with cancer treated at The Christie. Br J Cancer, 2024, 131(8): 1279-1289.
118. Chen W, Altshuler RD, Daschner P, et al. Older adults with cancer and common comorbidities-challenges and opportunities in improving their cancer treatment outcomes. J Natl Cancer Inst, 2024, 116(11): 1730-1738.
119. García-Pardo M, Chang A, Schmid S, et al. Respiratory and cardiometabolic comorbidities and stagesⅠto Ⅲ NSCLC survival: a pooled analysis from the International Lung Cancer Consortium. J Thorac Oncol, 2023, 18(3): 313-323.
120. Ayada G, Edel Y, Burg A, et al. Multidisciplinary team led by internists improves diabetic foot ulceration outcomes a before-after retrospective study. Eur J Intern Med, 2021, 94: 64-68.
121. An Q, Li Y, Shi J, et al. Promoting postoperative recovery in older adult surgical patients: a randomized controlled trial of MDT-based perioperative comprehensive nutritional management model. Front Nutr, 2025, 12: 1684807.
122. Herledan C, Toulemonde A, Clairet AL, et al. Enhancing collaboration between geriatricians, oncologists, and pharmacists to optimize medication therapy in older adults with cancer: a position paper from SOFOG-SFPO. Crit Rev Oncol Hematol, 2023, 190: 104117.
123. Basety S, Gudepu R, Velidandi A. Artificial intelligence in lung cancer: a narrative review of recent advances in diagnosis, biomarker discovery, and drug development. Pharmaceutics, 2026, 18(2): 491.
124. Huang S, Yang J, Shen N, et al. Artificial intelligence in lung cancer diagnosis and prognosis: current application and future perspective. Semin Cancer Biol, 2023, 89: 30-37.
125. Shen J, Feng S, Zhang P, et al. Evaluating generative AI models for explainable pathological feature extraction in lung adenocarcinoma: grading assessment and prognostic model construction. Int J Surg, 2025, 111(7): 4252-4262.
126. Zhu E, Muneer A, Zhang J, et al. Progress and challenges of artificial intelligence in lung cancer clinical translation. NPJ Precis Oncol, 2025, 9(1): 210.
127. Bonci EA, Bandura A, Dooley A, et al. Artificial intelligence in NSCLC management for revolutionizing diagnosis, prognosis, and treatment optimization: a systematic review. Crit Rev Oncol Hematol, 2025, 216: 104929.
128. Zhou D, Liu J, Zhang C, et al. Elevated serum total immunoglobulin E is associated with an increased risk of lung cancer: a retrospective study. Front Immunol, 2025, 16: 1637803.
129. Chen Y, Xing H, Yang X, et al. Patient-derived malignant effusion organoids guide tailored therapy and dissect third-generation EGFR-tyrosine kinase inhibitor resistance mechanisms in lung cancer. Cancer Lett, 2026, 645: 218356.
130. Zhou H, Zheng Z, Fan C, et al. Mechanisms and strategies of immunosenescence effects on non-small cell lung cancer (NSCLC) treatment: a comprehensive analysis and future directions. Semin Cancer Biol, 2025, 109: 44-66.
131. Wang R, Zheng J, Guo W, et al. Integrating a multimodal digital device for continuous perioperative monitoring in patients with lung cancer undergoing thoracic surgery: development and usability study. JMIR Mhealth Uhealth, 2025, 13: e69512.
132. Lee J, Kong S, Shin S, et al. Wearable device-based intervention for promoting patient physical activity after lung cancer surgery: a nonrandomized clinical trial. JAMA Netw Open, 2024, 7(9): e2434180.
133. Kvedar JC, Mittermaier M, Pritzker J. The industry impact of the American Medical Association’s Digital Medicine Payment Advisory Group (DMPAG). NPJ Digit Med, 2022, 5(1): 193.
134. Kim A, Chatterjee M, Iansavitchene A, et al. Artificial intelligence for electrocardiographic diagnosis of perioperative myocardial ischaemia: a scoping review. Br J Anaesth, 2025, 135(3): 561-570.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Latest ArticlesA novel perioperative comprehensive care model for elderly patients with lung cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content